Intramyocardial transfection with hypoxia inducible factor-1 alpha via an adenoviral vector during coronary artery bypass grafting – results of the phase I multi centre study

Abstract

Introduction: There are increasing numbers of patients who have advanced coronary artery disease (CAD) with limited percutaneous and/or surgical options for revascularization of ischemic cardiac muscle. We performed a prospective, randomized, double-blinded Phase I multicenter clinical trial to assess the feasibility and preliminary safety of delivering a multivalent, pro-angiogenic transcription factor termed „Hypoxia Inducible Factor-1 alpha“ (HIF-1a), delivered to ischemic cardiac muscle via a type 2 adenoviral vector (Genzyme Europe B.V., Netherlands).